What is 4D Molecular Therapeutics Inc (FDMT) stock price today?

4D Molecular Therapeutics Inc (FDMT) currently trades at $8.87 per share. The stock has a market capitalization of $479.88M and a P/E ratio of —x.

Is FDMT stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, 4D Molecular Therapeutics Inc has a Smart Value Score of 47/100 (Grade C), resulting in a "Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is 4D Molecular Therapeutics Inc's revenue and earnings?

4D Molecular Therapeutics Inc has trailing twelve-month (TTM) revenue of $85.21M with profit margins of -164.40%. Earnings per share (EPS) is $-2.42.

FDMT

4D Molecular Therapeutics Inc

NASDAQ: FDMT · HEALTHCARE · BIOTECHNOLOGY

$8.87

+0.68% today

Updated 2026-04-30

Market cap

$479.88M

P/E ratio

—

P/S ratio

5.63x

EPS (TTM)

$-2.42

Dividend yield

—

52W range

$3 – $12

Volume

0.8M

Market cap

$479.88M

P/E ratio

—

P/S ratio

5.63x

EPS (TTM)

$-2.42

Dividend yield

—

52W range

$3 – $12

Volume

0.8M

WallStSmart proprietary scores

out of 100

Grade: C

Sell

Investment rating

8.0

Growth

5.0

Quality

C+

3.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$28.78

+224.46%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy7 Buy2 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Free cash flow $27.92M — positive

+ Revenue growth 8,509,000.00% QoQ

Risks

- Thin margins at -164.40%

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$3.13M	$20.72M	$37000.00	$85.21M	$85.21M
Net income	$-101.08M	$-100.84M	$-160.87M	$-140.11M	$19.40M
EPS	—	—	—	—	$-2.42
Free cash flow	$-98.22M	$-78.56M	$-138.37M	$-109.62M	$27.92M
Profit margin	-3,230.30%	-486.59%	-434,778.38%	-164.43%	-164.40%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-25	SIMMS, CHRISTOPHER PAUL	Buy	219,000	—
2026-03-25	KIRN, DAVID	Buy	750,000	—
2026-03-25	BIZILY, SCOTT	Buy	217,000	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
FDMT	$479.88M	47	8.0	3.5	5.0	5.0	—	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

4D Molecular Therapeutics Inc trades at $8.87. Our Smart Value Score of 47/100 indicates the stock is fair. TTM revenue stands at $85.21M. with profit margins at -164.40%.

Frequently asked questions

What is 4D Molecular Therapeutics Inc's stock price?

4D Molecular Therapeutics Inc (FDMT) trades at $8.87.

Is 4D Molecular Therapeutics Inc overvalued?

Smart Value Score 47/100 (Grade C, Sell).

What is the price target of 4D Molecular Therapeutics Inc (FDMT)?

The analyst target price is $28.78, representing +224.5% upside from the current price of $8.87.

What is 4D Molecular Therapeutics Inc's revenue?

TTM revenue is $85.21M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio5.63x

ROE-27.60%

Beta2.93

50D MA$9.36

200D MA$8.53

Shares out0.05B

Float0.04B

Short ratio—

Avg volume0.8M

Performance

1 week-3.18%

1 month+1.29%

3 months+11.31%

YTD+26.00%

1 year—

3 years—

5 years—

Compare

FDMT vs LLY →FDMT vs JNJ →FDMT vs ABBV →Stock screener →